Peptide Synthesis and Purity Testing for MOTS-c and SS-31

Where a Research Vial Comes From

Users who run MOTS-c or SS-31 report mixed results. Sometimes they describe a bump in endurance or recovery. Other times, nothing. Part of that gap may be product quality, and part may be that neither compound has been tested for performance in healthy people (see our overview of the evidence on mitochondrial peptides).

Before blaming the peptide itself, it helps to look at its origin story. The journey from a chemical blueprint to the lyophilized powder in that vial is full of potential pitfalls. The synthesis process, the actual step-by-step construction of the peptide chain, decides what ends up in the vial. A failed step can leave a vial labeled SS-31 holding a mix of related but different molecules. As of October 2026, SS-31 (elamipretide) is also an FDA-approved prescription medicine, Forzinity, for Barth syndrome. Research-use vials aren't made or tested to that standard and aren't equivalent to it.

Building Peptides, Block by Block: SPPS Explained

For short peptides like these, the industry standard is a method called Solid-Phase Peptide Synthesis (SPPS). Its inventor, Bruce Merrifield, won the 1984 Nobel Prize in Chemistry for it. Most labs now use the Fmoc version, named for the temporary protecting group that caps the growing end of the chain between steps. Think of it like building with LEGOs, but on a microscopic scale.

Here's the simplified version. Scientists start with a tiny, insoluble bead of plastic called a resin. They chemically anchor the first amino acid of the peptide chain to this bead. This is the foundation. Then, they flood the system with the second amino acid, which has been chemically primed to link up, or couple, with the first one. After the connection is made, they perform a wash step to remove all the leftover, unattached amino acids. Then they remove the Fmoc cap from the new end of the chain so it's ready for the next amino acid. Lather, rinse, repeat. You build the entire peptide, one amino acid at a time, while it's safely stuck to that solid resin bead. This step-by-step process with washes in between is what allows for a specific sequence, though not a perfectly pure one.

Once the full chain is built (16 amino acids for MOTS-c, for example), the final step is cleavage. This is where a chemical cocktail, usually a strong acid, cuts the completed peptide off the resin bead and removes any temporary protective chemical groups used during the synthesis. What you're left with is crude peptide: the target plus any failed sequences, ready to be purified (usually by reverse-phase HPLC) and freeze-dried.

Synthesis-Related Impurities

SPPS is reliable, but it isn't foolproof. Each amino acid needs at least a deprotection and a coupling step, so even 16-residue MOTS-c involves more than 30 reactions. If every coupling worked 99% of the time, simple arithmetic says only about 86% of chains would come out full-length. The rest are different molecules that just happen to be in your vial unless purification removes them.

A 2014 review of impurities in peptide medicines describes the common culprits:

• Truncated Sequences: The coupling reaction fails, and the chain stops growing. If you're trying to make a 16-amino-acid peptide like MOTS-c and the reaction stalls at amino acid #10, you now have a 10-amino-acid fragment. It's not MOTS-c, and there's no reason to expect it to work like MOTS-c.

• Deletion Sequences: A coupling or deprotection step is incomplete, but the synthesis continues. An amino acid gets skipped entirely, so the peptide is one residue short. The review links deletions to inefficient Fmoc removal. Because a deletion peptide is so close to the target, it can be hard to purify out, and nobody has tested whether MOTS-c deletion variants keep any activity.

• Racemization: Fmoc removal can flip an amino acid into its mirror-image form, creating a molecule with exactly the same mass as the target. The review also lists insertions (an extra amino acid) and leftover protecting groups.

• TFA counter-ions: Peptides purified by reverse-phase HPLC are often isolated as trifluoroacetate (TFA) salts. A 1999 cell-culture study found that low concentrations of TFA slowed the growth of rat bone and cartilage cells, enough to mask a peptide's measured effect. What residual TFA means for people injecting research peptides hasn't been studied (for the wider safety picture, see long-term health implications of mitochondrial peptides). The Forzinity label lists elamipretide as a hydrochloride salt.

• Endotoxin: Bacterial fragments that can cause fever if injected. HPLC purity doesn't detect them; that takes a separate test, usually the LAL assay.

Think about SS-31 (Elamipretide). It's only four amino acids long: D-Arg-2,6-dimethyl-Tyr-Lys-Phe-NH2, according to the Forzinity label, which describes it as a mitochondrial cardiolipin binder. The arginine is deliberately the D (mirror-image) form. If a lab used ordinary L-arginine by mistake, or racemization flipped a residue, the product would have the same mass as SS-31, so a mass spectrometry check would pass it. Only an HPLC method shown to separate the two forms would catch it.

Decoding a Certificate of Analysis (CoA)

A Certificate of Analysis (CoA) is vendor-supplied evidence: a document the seller provides, sometimes from its own lab and sometimes from a contract lab. It usually includes a purity result from High-Performance Liquid Chromatography (HPLC) and often a mass spectrometry result for identity.

HPLC is a technique that separates the components of a mixture. You dissolve the peptide and run it through a column. Different molecules travel at different speeds, and a detector at the end charts the results. A pure sample will show one big, dominant peak. A contaminated sample will show the main peak plus smaller ones, which can include the truncated and deletion sequences above. Mass spectrometry checks something else: whether the main molecule has the expected molecular weight.

The CoA will list a purity percentage derived from the HPLC test. It's a useful starting point, but it's a share of what the detector sees, not the amount of peptide in the vial, so a vial can test 99% pure and still hold less than the label says. Endotoxin needs its own test. A CoA also describes one batch, and users on peptide forums report CoAs reused across batches or altered; we couldn't measure how common that is.

What HPLC Purity Levels Mean In Practice

None of these numbers says anything about endotoxin or how much peptide the vial contains.

What Independent Testing Shows

A preprint posted in April 2026 (not yet peer-reviewed) analyzed 6,441 results from a public third-party testing dataset covering 14 peptides. Depending on how strict the benchmark was, 41.6% to 71.1% of samples failed basic purity, quantity or identity standards, and endotoxin was measurable in 15% of the 243 samples tested for it. MOTS-c and SS-31 weren't among the 14; as of October 2026 we found no comparable independent data for either.

When you see someone online say, "I tried MOTS-c and it did nothing," product quality is a fair question, but it isn't the only one. As of October 2026, no peer-reviewed study has given native MOTS-c to people (see our MOTS-c research notes), so a lack of effect could also mean the compound does little in humans at the doses users report. A clean CoA rules out some synthesis problems; it can't settle that question.